LMO2 and leukemia: There may be a risk involving the oncogenic potential of LMO2 in reprogrammed cells [95], particularly given the appearance of leukaemias in the X-SCID trials following retroviral insertional activation of LMO2 [9,10,38] and the evidence of neoplasia in models of enforced lmo2 expression [87–89,96].